Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials

Main Article Content

Eric Simpson
Joseph Merola
Jonathan Silverberg
Rebecca Zachariae
Rebecca Olsen
Andreas Wollenberg

Keywords

Atopic Dermatitis, Biologic, Tralokinumab, IL-13, Safety

Abstract

Abstract not available.

References

1. Nutten S. Ann Nutr Metab 2015; 66(Suppl 1): 8–16.

2. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

3. Eckert L et al. J Am Acad Dermatol 2017; 77: 274–279.e273.

4. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

5. Dalgard FJ et al. J Invest Dermatol 2015; 135: 984–991.

6. Bieber T. Allergy 2020; 75: 54–62.

7. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

8. Popovic B et al. J Mol Biol 2017; 429: 208–219.

9. Wollenberg A et al. J Allergy Clin Immunol 2019; 143: 135–141.

10. Augustin M et al. J Eur Acad Dermatol Venereol 2020; 34: 142–152.

Most read articles by the same author(s)

1 2 > >>